The in vitro test confirms Brilacidin's antiviral activity against Covid19. It ignores other factors which will be tested in the human clinical trials which may prove to be even more important.
Brilacidin is virucidal. It kills the virus quickly. It has 3 possible mechanisms of action which make resistance unlikely and may allow it to be effective against multiple viruses including MERs,SARS,Encephalitis and Influenza. It can kill the virus by opening its capsized or outer membrane. It can prevent infection by binding the S protein to prevent attachment to the ACE binding site. It can prevent viral replication by binding the main protease.
The ABSSSI trial also confirmed Brilacidin's excellent pharmacodynamics and safety. It has a long half life which will reduce the frequency of administration and maintain serum levels to continue killing the virus for days,maybe even one IV dose.
Many of our competitors drugs are derived from monoclonal antibodies like Regenron's triple therapy and may have severe safety issues Tolcilizumab is being proposed as an anti-inflammatory to reduce the pulmonary complications of Covid 19, but has an 18% rate of inducing pneumonia.
Brilacidin's immunomodulating effects are unique for an antiviral and may reduce the cytokine storm and severe pulmonary inflammation and exudation which are the most common cause of mortality with Covid 19. In addition its antibiotic action will reduce secondary infections.
The RBL lab just demonstrated one aspect of Brilacidin's biologic actions. The clinical trials with real patients is where I expect it to shine using all of its properties to treat Covid 19.
It is a completely unique and special pharmaceutical.
JMO
Glta,Farrell
Market Data 
Markets 
AI
